See What HealthDay Can Do For You
Contact Us

Exenatide, Pioglitazone Effective for Poorly Controlled T2DM

Findings in patients with long-standing poorly controlled type 2 diabetes on metformin, sulfonylurea

glucose test

MONDAY, Jan. 23, 2017 (HealthDay News) -- For patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea, combination therapy with exenatide and pioglitazone is effective and safe, according to a study published online Jan. 17 in Diabetes Care.

Muhammad Abdul-Ghani, M.D., Ph.D., from Hamad General Hospital in Doha, Qatar, and colleagues randomized 231 patients with poorly controlled T2DM on a sulfonylurea plus metformin to receive combination therapy (pioglitazone plus weekly exenatide) or insulin therapy (basal plus prandial insulin) to maintain hemoglobin A1c (HbA1c) <7.0 percent.

The researchers found that combination therapy decreased HbA1c from 10.0 ± 0.6 percent at baseline to 6.1 ± 0.1 percent after a mean follow-up of 12 months, compared with 7.1 ± 0.1 percent in those receiving insulin therapy. Combination therapy reduced the HbA1c, regardless of sex, ethnicity, body mass index, or baseline HbA1c. Compared with patients in the combination therapy group, subjects in the insulin therapy group experienced significantly greater weight gain and a three-fold higher rate of hypoglycemia.

"Combination exenatide/pioglitazone therapy is a very effective and safe therapeutic option in patients with long-standing poorly controlled T2DM on metformin plus a sulfonylurea," the authors write.

One author disclosed financial ties to pharmaceutical companies, including Astra Zeneca, which provided the exenatide.

Full Text (subscription or payment may be required)

Physician's Briefing